喜訊！東曜藥業(1875.HK)榮獲蘇州工業園區2019年度科技企業上市獎和科技研發突出獎
2020年03月06日，蘇州工業園區召開“建設世界一流高科技園區 打造新時代改革開放新高地”誓師大會。會上，對於蘇州工業園區的先進企業和優秀人才進行了表彰。東曜藥業有限公司同時榮獲2019年度 “科技企業上市獎”和“科技研發突出獎”兩項殊榮。
港交所上市
東曜藥業自2010年7月在蘇州設立，紮根園區、創新發展，專注於創新型腫瘤藥物及療法的開發及商業化，致力於打造患者、家屬及醫療專業人士信賴的腫瘤治療領先品牌。2019年11月，東曜藥業成功在香港港交所主板上市，股票代號：1875.HK。
創新技術
近年來，東曜藥業持續加大投入，完成了設計產能達到16,000升的抗體藥商業化生產基地建設，並開展技術創新和產品研發。東曜藥業開發了多個系列、多個品種的抗腫瘤藥物，已經有6 種在研藥物處於臨牀及以上關鍵階段，形成了完整、高質量的藥物產品鏈。
公司自主研發了灌注-批式混合細胞擴增技術（PB-Hybrid Technology），是國內首個將該技術應用到上市規模的生產的企業，並已完成多產品多批次的生產和驗證，成為公司成熟的平台技術。該技術顛覆了單抗大規模生產細胞擴增的傳統工藝，僅由25L即可直接擴大到2000L規模，省去了10L、50L、200L、500L擴增步驟，簡化工藝流程、優化產品質量、縮短生產週期、減少資本支出，具備極高的生產競爭優勢。
東曜藥業潛心鑽研抗體偶聯藥物（ADC）技術數年，已經完成ADC產品TAA013的研發、中試放大、I期臨牀研究數據發佈；完成了策略合作伙伴的數個新一代ADC藥物的研發與生產。東曜藥業正在建設中的ADC藥物車間，將成為國內少數幾間符合GMP要求的ADC商業化生產車間之一，為公司在ADC領域的發展奠定基礎並搶佔市場先機。
開放合作 追求突破
東曜藥業佈局全產業鏈，建設集研發、臨牀試驗、製造、商業化於一體的綜合全產業鏈平台。我們積極開放合作平台，拓展創新藥品開發立項,並透過國際合作，引入更多創新機遇，奮力追求新突破。
此次獲評殊榮是對東曜藥業近年來發展的認可和肯定，未來東曜藥業將堅持人文與科技平衡的經營理念，繼續加大創新、開拓進取，為蘇州工業園區經濟發展做出新的貢獻。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
